#Taiwan #Taipei #biotechnology #Onward Therapeutics

Onward Therapeutics Completes Share Exchange and Establishes Global Headquarters in Taiwan

Onward Therapeutics is making a significant leap in its global strategy by establishing its global headquarters in Taiwan as part of a recent share exchange. This milestone marks a defining moment in the company's history, enhancing its operational efficiency and expanding its potential across Asia and Europe.

Strategic Reorganization

In a major organizational shift, Onward Therapeutics, Inc. has transitioned to being the main holding and management entity situated in Taiwan. Meanwhile, its previous parent company, Onward Therapeutics SA located in Switzerland, is now a wholly owned subsidiary of the Taiwanese entity. This share exchange was executed while maintaining the existing ownership ratios and the overall board structure, thereby ensuring continuity and stability in oversight and governance.

This restructuring not only reflects the company's strategic focus on aligning its corporate structure with Taiwan's robust biotechnology ecosystem but also aims to capitalize on the investment opportunities in Taiwan’s dynamic capital market. By uniting its scientific and corporate teams from Taiwan, Switzerland, and France under a single umbrella, Onward is positioning itself for further innovation and collaboration in the biotech space.

Enhancing Global Operations

Over the last six years, Onward has developed a strong pipeline focused on novel therapies targeting solid and hematologic tumors. The recent organizational changes are crafted to not only streamline operations but also to support broader growth plans, including future fundraising activities and avenues for a potential public listing. This move is expected to enhance Onward's ability to accelerate its global programs and foster new partnerships, leveraging Taiwan's established regulatory framework and advanced clinical trial infrastructure.

Taiwan's unique blend of scientific excellence and a robust investment environment provides a fertile ground for Onward to advance its mission to develop innovative cancer treatments. This strategic relocation is seen as a vital step towards financial sustainability and creating a lasting impact in the biotechnology field.

Leadership Insights

Dr. C. Grace Yeh, the Founder and CEO of Onward Therapeutics, expressed great appreciation for the unanimous approval of this pivotal share exchange by shareholders. She emphasized that establishing a global headquarters in Taiwan symbolizes not only a significant achievement for Onward but also represents a practical response to the needs and opportunities within the biotechnology sector. The blend of innovation, efficiency, and connectivity in Taiwan forms the cornerstone of Onward's future growth strategies.

Onward Therapeutics focuses on developing multi-modality therapies aimed at overcoming cancer resistance. The company’s research endeavors include cutting-edge projects such as a bispecific antibody and an allogeneic NK cell therapy, along with groundbreaking early development programs in onco-metabolism and multi-specific antibodies. Such advances underline Onward’s commitment to pioneering solutions in the fight against cancer.

Conclusion

With its headquarters now firmly established in Taiwan, Onward Therapeutics is set to enter a new chapter in its journey toward enhancing the landscape of biopharmaceuticals. The completion of the share exchange signifies the company's unwavering dedication to continuous innovation and global expansion. It is a promising time for Onward as it aims to improve lives through transformative cancer therapies, backed by the strong foundations and supportive ecosystem in Taiwan.